ArticlePloS one2017
Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Fetal Bovine Hide Collagen-Chitosan Composite Sponges: Preparation, Physicochemical Profiling, and Cutaneous Wound Healing Efficacy.Polymers · 2026Article
- Efficient multi-lineage cardiovascular differentiation of human pluripotent stem cells in animal serum-free conditions.Scientific reports · 2026Article
- From dairy by-product to cell feed: milk whey for serum-free media and scaffold development in cell-based food production.NPJ science of food · 2026Review
- Review
- Canonical Wnt signaling affects calcium homeostasis in serum-treated AC16 cells through MLN-mediated SERCA2a regulation.Journal of molecular cell biology · 2026Article
- Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture.Biological research · 2026Review
- Effects of low-serum adaptation on growth and protein expression in stably lactoferrin-overexpressing mammary alveolar cells.Frontiers in bioengineering and biotechnology · 2026Article
- Production, pricing, and incentives in the fetal bovine serum market.Translational animal science · 2026Article
- Comparison of prostate cancer cell line growth in fetal bovine serum and animal free supplements.Molecular biology reports · 2025Article
- Plasma-Depleted Lyophilized Porcine Platelet Lysate as an Alternative to Fetal Bovine Serum in Cell Culture.Life (Basel, Switzerland) · 2025Article
- Optimizing Lentiviral Vector Production: Insights Into PiggyBac Transposase and Concatemeric Array Strategies.Biotechnology journal · 2025Article
- Article
- Increasing the biomolecular relevance of cell culture practice.Journal of biomedical science · 2025Review
- Host-mimicking conditions promoteFrontiers in microbiology · 2025Article
- Ultrastructural Visualization of the Nuclear Envelope in HeLa Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Conditioned serum-free culture medium accomplishes adhesion and proliferation of bovine myogenic cells on uncoated dishes.NPJ science of food · 2024Article
- Exploring cost reduction strategies for serum free media development.NPJ science of food · 2024Review
- Preliminary study on comparison of egg extraction methods for development of fetal bovine serum substitutes in cultured meat.Food chemistry: X · 2024Article
- Biochemical and functional characterization of heat-inactivated coelomic fluid from earthworms as a potential alternative for fetal bovine serum in animal cell culture.Scientific reports · 2024Article
- Macrophage variants in laboratory research: most are well done, but some are RAW.Frontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal bovine serum (FBS) is depended upon by investigators as an indispensable supplement in cell and tissue culture systems. Due to increased demand and limited availability, the price of FBS has increased by greater than 300% in the past few years. In addition, there are ethical and scientific controversies about the collection and use of FBS in culture systems. In response to the shortage of FBS, many FBS alternative serum products have been developed. Although many have claimed comparable performance to FBS, their support of long-term cell growth and effects on cell phenotype have not been revealed. In this study, we examined the performances of six bovine calf serum-based FBS alternatives in six head and neck cell lines and compared them with FBS. The results indicate that some of these sera had growth promoting capabilities comparable or superior to that of FBS. Additionally, these alternative sera supported long-term (30 passages) growth of tested cells and exhibited plating efficiencies comparable to that of FBS. Cells cultured in alternative sera also exhibited comparable anchorage-independent growth and similar drug inhibition responses in FBS. Still, caution should be taken in choosing suitable sera given that changes in cell morphology and variations in chemotactic responses were noted for cells maintained in certain sera. These FBS alternatives are more readily available, cost less, and are associated with less ethical concerns, thus making them attractive alternatives to FBS in cell culture systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.